Radiation beads aim to shrink liver tumors in neuroendocrine cancer trial
NCT ID NCT04362436
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase II trial tested a treatment called TheraSphere selective internal radiation therapy (SIRT) in 24 patients with neuroendocrine tumors that had spread to the liver and could not be surgically removed. The treatment involves injecting tiny radioactive beads into the liver's blood supply to deliver radiation directly to tumors. The study measured safety, tumor shrinkage, and how long patients lived without their disease getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College NHS Trust
London, W12 0HS, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TheraSphere (yttrium-90 glass microspheres) for selective internal radiation therapy
What this could lead to
If successful, this could offer a new treatment option for patients with inoperable liver metastases from neuroendocrine tumors, potentially improving tumor control and survival.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply broadly. Radiation to the liver carries risks of liver damage, fatigue, and other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.